ENTITY
Laekna

Laekna (2105 HK)

23
Analysis
Health Care • Hong Kong
Laekna, Inc. operates as a clinical-stage biotechnology company. The Company researches and develops adenosine triphosphate (ATP) competitive protein kinase B (AKT) inhibitor and androgen synthesis inhibitor. Laekna applies its products for the treatment of ovarian cancer, prostate cancer, breast cancer, and prostate cancer.
more
•21 Dec 2025 08:30

APAC Healthcare Weekly (December 21)–Fosun Pharma, Hansoh, Daiichi Sankyo, Takeda, Hanmi, Max Health

Fosun Pharma is acquiring 53% stake in Green Valley. Hansoh inked exclusive license agreement with Glenmark Pharma. Daiichi Sankyo’s Enhertu got...

Logo
451 Views
Share
bullish•Quantitative Analysis
•14 Dec 2025 10:05

HK Connect Flows Weekly (Dec 12th): Xiaomi Inflows & Tencent/Alibaba Outflows

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Xiaomi, Tencent, CMB, Alibaba, Zhejiang Leapmotor...

Logo
312 Views
Share
bullish•Quantitative Analysis
•07 Dec 2025 10:05

HK Connect Flows Weekly (Dec 5th): Alibaba, Meituan, Pop Mart Intl, SMIC, Zijin Mining, Xiaomi

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Meituan, Pop Mart Intl, SMIC, Zijin Mining,...

Logo
335 Views
Share
bullish•Quantitative Analysis
•23 Nov 2025 10:05

HK Connect Flows Weekly (Nov 21st): Alibaba, Xiaomi, Xpeng, CCB, SMIC, China Shenhua Energy

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, Xiaomi, Xpeng, CCB, SMIC, China Shenhua Energy.

Logo
531 Views
Share
•16 Nov 2025 08:30

APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics

Henlius got FDA approval for Perjeta biosimilar. Otsuka reports positive Phase 3 trial result for sibepernlimab. ABL Bio signed deal with Lilly....

Logo
498 Views
Share
x